![]() |
|
Advent gives SEP acquisition boost
Speciality European Pharma (SEP) has secured €15 million (£10 million) from Advent Venture Partners. The investment is SPE’s first major financing round.
London-based SEP has used the financing to buy Swiss pharmaceutical company Proreo Pharma International. It also acquired the worldwide rights to Plenaxis - a treatment for prostate cancer - from US company Praecis Pharmaceuticals Plenaxis.
SEP’s chief executive Geoff McMillan says: 'The rationale for founding SEP was to acquire products with potential for a broader pan-European appeal and these two acquisitions very much fall into that sweet-spot.'
Launched by Advent in September 2006, SEP acquires pharmaceutical prescription products to develop and market in Europe. Rather than raising a war chest, the company will seek funding for specific acquisitions.
Advent has more than £500 million under management. General partner Patrick Lee is a non-executive director at SEP.

Related Articles |
Interesting links
Other Sector Watch
- Talking rubbish Jul 28 2008
- Crisis?– what crisis? Jul 01 2008
- Let the
drilling begin
May 13 2008 - Bargains on the high street
Mar 13 2008 - Sowing the seed Mar 03 2008
M&A News
- AWS on global spending spree Oct 07 2008
- Hamsard 3137 acquires Bodycare Oct 07 2008
- Acquisitions for media firms Oct 06 2008
- Twin coup for Digital Marketing Group Oct 06 2008
- Asia survives global deep freeze Oct 03 2008
Special Offers
- 2008 AIM Guide: Jul 17 2007
- Growth Company Investor Magazine: Jul 17 2007
- Cash Shells 2007 - Research report Jul 17 2007
- Venture Capital Trusts Jul 04 2007
M&A Deals
- Double crane acquisition for EnerMech Oct 07 2008
- Spa company escapes with Capital cash Oct 07 2008
- Xchanging studies Cambridge Solutions deal Oct 06 2008
- Digital Marketing celebrates double deal Oct 06 2008
- Brains behind expansion into North West Oct 03 2008
Business Diary
- M&A Expanding internationally 27th November
- Rosenblatt New Energy Awards 2009 25th February
- Business XL How to float on AIM 11th November
